Lexicon Pharma (LXRX) Tops Q3 EPS by 7c, Miss on Revenues
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.34 --0%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
HSAI, SYRS, EGRX, More
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
HSAI, SYRS, EGRX, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q3 EPS of ($0.29), $0.07 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $26.94 million versus the consensus estimate of $27.96 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Klarna shares tumble on weak full-year revenue guidance
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
- Sypris Solutions (SYPR) Reports Q2 Loss of $0.14
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
